At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV ...

Daily oral PrEP (generic Truvada; Descovy) is effective but adherence-sensitive, and seroconversions in trials correlate with ...

The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

On top of offering various PrEP and PEP medications to students, Student Health expanded its HIV prevention medications this semester with lenacapavir, a twice-per-year injection the Food and Drug ...

The HIV epidemic remains a critical public health priority in the United States. The Ending the HIV Epidemic (EHE) initiative seeks to reduce HIV diagnoses by 75% by 2025 and by 90% by 2030. Certain ...

The U.S. Preventive Services Task Force released a recommendation this week calling on health care providers to prescribe all approved PrEP options for people at ...

Much has changed in the world of HIV pre-exposure prophylaxis (PrEP) in the four years since COVID-19 shut down the world — from delivery methods to length of time between treatments. In 2024, there ...

Carl Schmid and his colleagues got more than they bargained for -- in a good way -- when they requested that Medicare cover long-acting physician-administered HIV pre-exposure prophylaxis (PrEP) drugs ...

Add Yahoo as a preferred source to see more of our stories on Google. HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these ...

A long-awaited court decision has finally arrived, with disturbing health implications: The ruling exempts select employers from fully covering a daily pill that can prevent a person’s chances of ...